Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $110.4286.

Several equities research analysts have recently weighed in on LNTH shares. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Citizens Jmp reissued a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a research report on Monday, June 29th. Citigroup restated an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Finally, B. Riley Financial increased their price objective on shares of Lantheus from $97.00 to $129.00 and gave the company a “buy” rating in a research report on Thursday, July 9th.

Lantheus Stock Performance

NASDAQ:LNTH opened at $104.82 on Friday. The firm’s fifty day simple moving average is $103.36 and its 200 day simple moving average is $85.56. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus has a twelve month low of $47.25 and a twelve month high of $111.86. The firm has a market capitalization of $6.82 billion, a price-to-earnings ratio of 25.26 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same period in the prior year, the firm earned $1.53 EPS. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts expect that Lantheus will post 4.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LNTH. Western Wealth Management LLC purchased a new stake in Lantheus during the 1st quarter worth $25,000. Osterweis Capital Management Inc. acquired a new position in Lantheus in the 2nd quarter worth $36,000. Smartleaf Asset Management LLC lifted its holdings in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Bessemer Group Inc. boosted its position in Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.